Gibson Christopher 4

What Happened

Christopher Gibson, a director of Recursion Pharmaceuticals (RXRX), converted 40,000 Class B shares into Class A common stock and sold those 40,000 shares in an open-market transaction on Feb 4, 2026 at $4.12 each, generating $164,800 in proceeds. On Feb 6, 2026 he was granted/issued 30,346 restricted stock units (RSUs) that vested immediately; 10,364 of those shares were withheld to satisfy tax withholding (valued at $3.56 each, $36,896), leaving 19,982 net shares issued to him.

Key Details

• Transaction dates and prices:
  • Feb 4, 2026: Conversion of 40,000 Class B → Class A (derivative conversion) and sale of 40,000 shares at $4.12 ($164,800) — sale executed pursuant to a Rule 10b5-1 plan adopted May 12, 2025 (F2, F1).
  • Feb 6, 2026: Grant/vesting of 30,346 RSUs (vested immediately per F3); 10,364 shares withheld for taxes at $3.56 ($36,896) (F4).
• Transaction codes: C = conversion of derivative security; S = sale; A = award/grant; F = shares withheld for taxes.
• Shares owned after the transactions: Not disclosed in this filing.
• Filing timing: Report filed Feb 6, 2026 covering Feb 4–6 transactions; no late filing indicated (Form 4 is generally due within two business days).
• Notable footnotes: Class B shares are convertible into Class A at holder’s option with no expiration (F1). Sale was under a pre-established 10b5-1 trading plan (F2). RSU vested immediately (F3) and shares were withheld to cover tax withholding (F4).

Context

• The Feb 4 sale was carried out under a pre-set 10b5-1 plan, which is a routine mechanism insiders use to sell shares and typically reduces concerns about opportunistic timing.
• The Feb 6 activity reflects an RSU vesting with net settlement (shares withheld to pay taxes), not a voluntary market sale of those vested shares.
• Purchases are usually viewed as stronger bullish signals than sales; here the notable cash event is the planned sale (40,000 shares).